David Bell
Direktor/Vorstandsmitglied bei BIOTEST AG
Vermögen: 184 895 $ am 30.04.2024
Profil
Dr. David I.
Bell is a Chief Corporate Development & Legal Officer at Grifols SA, a Vice President-Corporate Operations & Development at Grifols USA, Inc., a Chief Executive Officer at Biomat USA, Inc., a Chief Executive Officer at Grifols Bio Supplies, Inc. and a President & Chief Executive Officer at Grifols Innovation & New Technologies Ltd.
He is on the Board of Directors at Biotest AG, Shanghai RAAS Blood Products Co., Ltd., Plasma Protein Therapeutics Association, Alkahest, Inc., BPC Plasma, Inc., GigaGen, Inc., Singulex, Inc. and Theriva Biologics SL.
Dr. Bell was previously employed as a Vice President-Operations & Development by Grifols, Inc., a Vice President & General Counsel by Alpha Therapeutic Corp., a Member by California State Bar Association, and a Partner by Knapp, Petersen & Clarke PC.
He also served on the board at Aradigm Corp.
He received his undergraduate degree from the University of California, Irvine, a graduate degree from Southwestern Law School and a graduate degree from Harvard Law School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GRIFOLS, S.A. CLASS A
0,00% | 31.12.2023 | 20 000 ( 0,00% ) | 184 895 $ | 30.04.2024 |
Aktive Positionen von David Bell
| Unternehmen | Position | Beginn |
|---|---|---|
| GRIFOLS, S.A. | General Counsel | 01.07.2003 |
| SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. | Direktor/Vorstandsmitglied | 20.05.2020 |
| BIOTEST AG | Direktor/Vorstandsmitglied | 01.06.2022 |
Grifols USA, Inc.
 Grifols USA, Inc. Medical SpecialtiesHealth Technology Grifols USA, Inc. sales and markets automated analyzers and dosing machines. The company supplies plasma products, diagnostic reagents, analyzers and dosing machines. Grifols USA was founded in 1948 and is headquartered in Los Angeles, CA. | General Counsel | 01.07.2003 |
Alkahest, Inc.
 Alkahest, Inc. BiotechnologyHealth Technology Alkahest, Inc. operates as biopharmaceutical company. It focuses on developing of treatments for neurodegenerative and age-related diseases. The company is headquartered in San Carlos, CA. | Direktor/Vorstandsmitglied | - |
VCN Biosciences SL
 VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The private company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Direktor/Vorstandsmitglied | - |
BPC Plasma, Inc.
 BPC Plasma, Inc. Pharmaceuticals: MajorHealth Technology BPC Plasma, Inc. manufactures pharmaceutical products. It offers the hyper immunoglobulin Nabi-HB, a key product used in the prevention of hepatitis B. The company was established in 2007 and is headquartered in Boca Raton, FL. | Direktor/Vorstandsmitglied | - |
Singulex, Inc.
 Singulex, Inc. Miscellaneous Commercial ServicesCommercial Services Singulex, Inc. provides biotechnological research and development services. It also provides instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. The company was founded by Robert S. Puskas in November 1997 and is headquartered in Alameda, CA. | Direktor/Vorstandsmitglied | - |
GigaGen, Inc.
 GigaGen, Inc. BiotechnologyHealth Technology GigaGen, Inc. engages in the provision of single cell droplet technology to clinical researchers and physicians. The firm's patent-pending technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize genetic data from cells circulating in blood. Its technology can be applied in immunology, infectious disease monitoring, noninvasive prenatal diagnostics, and noninvasive cancer detection. The company was founded by David S. Johnson and Everett Meyer in 2010 and is headquartered in South San Francisco, CA. | Direktor/Vorstandsmitglied | - |
| ░░░░░░░ ░░░░░░░░░░ ░░░░░ ░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | - |
Ehemalige bekannte Positionen von David Bell
| Unternehmen | Position | Ende |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░ ░░░ ░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░░░ ░░░░░░░ | - |
| ░░░░░░ ░░░░░░░░ ░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von David Bell
| Harvard Law School | Graduate Degree |
| Southwestern Law School | Graduate Degree |
| University of California, Irvine | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| GRIFOLS, S.A. | Health Technology |
| SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. | Health Technology |
| BIOTEST AG | Health Technology |
| Private Unternehmen | 15 |
|---|---|
Grifols USA, Inc.
Grifols USA, Inc. Medical SpecialtiesHealth Technology Grifols USA, Inc. sales and markets automated analyzers and dosing machines. The company supplies plasma products, diagnostic reagents, analyzers and dosing machines. Grifols USA was founded in 1948 and is headquartered in Los Angeles, CA. | Health Technology |
| California State Bar Association | |
Aradigm Corp.
 Aradigm Corp. Pharmaceuticals: MajorHealth Technology Aradigm Corp. was a pharmaceutical company, which was focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. The company was founded in 1991 and was headquartered in Hayward, CA. | Health Technology |
Grifols, Inc.
 Grifols, Inc. Pharmaceuticals: MajorHealth Technology Grifols, Inc. manufactures pharmaceuticals. The company is headquartered in Los Angeles, CA. | Health Technology |
Plasma Protein Therapeutics Association
 Plasma Protein Therapeutics Association Miscellaneous Commercial ServicesCommercial Services The Plasma Protein Therapeutics Association is a non-profit organization that represents manufacturers and plasma collection centers. The private company is based in Washington and has subsidiaries in the United States. Anita Brikman has been the CEO of the American company since 2023. | Commercial Services |
Biomat USA, Inc.
 Biomat USA, Inc. Medical/Nursing ServicesHealth Services Biomat USA, Inc. provides plasma derived blood products. The company is headquartered in Los Angeles, CA. | Health Services |
Grifols Innovation & New Technologies Ltd.
 Grifols Innovation & New Technologies Ltd. BiotechnologyHealth Technology Grifols Innovation & New Technologies Ltd. provides research and experimental development services in biotechnology sector. The company was founded on December 21, 2015 and is headquartered in Dublin, Ireland. | Health Technology |
Alpha Therapeutic Corp.
 Alpha Therapeutic Corp. BiotechnologyHealth Technology Part of Grifols SA/Grifols Family/, Alpha Therapeutic Corp. develops plasma derived products. The private company is based in Los Angeles, CA. | Health Technology |
GigaGen, Inc.
GigaGen, Inc. BiotechnologyHealth Technology GigaGen, Inc. engages in the provision of single cell droplet technology to clinical researchers and physicians. The firm's patent-pending technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize genetic data from cells circulating in blood. Its technology can be applied in immunology, infectious disease monitoring, noninvasive prenatal diagnostics, and noninvasive cancer detection. The company was founded by David S. Johnson and Everett Meyer in 2010 and is headquartered in South San Francisco, CA. | Health Technology |
Singulex, Inc.
Singulex, Inc. Miscellaneous Commercial ServicesCommercial Services Singulex, Inc. provides biotechnological research and development services. It also provides instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. The company was founded by Robert S. Puskas in November 1997 and is headquartered in Alameda, CA. | Commercial Services |
Alkahest, Inc.
Alkahest, Inc. BiotechnologyHealth Technology Alkahest, Inc. operates as biopharmaceutical company. It focuses on developing of treatments for neurodegenerative and age-related diseases. The company is headquartered in San Carlos, CA. | Health Technology |
Knapp, Petersen & Clarke PC
 Knapp, Petersen & Clarke PC Miscellaneous Commercial ServicesCommercial Services Knapp, Petersen & Clarke PC is a law firm that offers a variety of legal services. The private company is based in Glendale, CA. The firm emphasizes its creativity and accessibility in providing these services. | Commercial Services |
BPC Plasma, Inc.
BPC Plasma, Inc. Pharmaceuticals: MajorHealth Technology BPC Plasma, Inc. manufactures pharmaceutical products. It offers the hyper immunoglobulin Nabi-HB, a key product used in the prevention of hepatitis B. The company was established in 2007 and is headquartered in Boca Raton, FL. | Health Technology |
VCN Biosciences SL
VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The private company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Commercial Services |
Interstate Blood Bank, Inc.
 Interstate Blood Bank, Inc. Medical SpecialtiesHealth Technology Interstate Blood Bank, Inc. engages in the provision of human blood and blood components to the therapeutic and diagnostic industries. The company was founded in 1949 and is headquartered in Memphis, TN. | Health Technology |
